Results 101 to 110 of about 2,414,633 (297)

Higher Complement C4 Gene Copy Number Constitutes a Shared Genetic Risk Factor for Giant Cell Arteritis and IgA Vasculitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Low copy number (CN) of complement C4 isoforms and high CN of retroviral HERV‐K elements are known risk factors for many immune‐mediated inflammatory diseases (IMIDs), often showing sex‐biased effects. Here, we assessed whether CN variation within the C4 gene contributes to giant cell arteritis (GCA) and IgA vasculitis (IgAV), two complex ...
Laura Martínez‐Gutiérrez   +295 more
wiley   +1 more source

John Adam Street [Adelphi development]

open access: yes
Number 8 John Adam Street (Royal Society for the Encouragement of Arts, Manufactures and Commerce), detail, medallion; Adam House (7-10 John Adam Street) is part of the Adelphi development designed in 1768-1772 by brothers Robert and John Adam.
Adam, John, Adam, Robert
core  

ADAM Report 1

open access: yes, 1993
ADAM REPORT # 1, October 1993 1. Basic Features of Enterprise Agreements 2. Emerging Trends 3.
ACIRRT
core  

The Nuclear Receptor Testicular Receptor 4 Orchestrates Cytoskeletal Organization in a G Protein Subunit Alpha 12/Rho‐Associated Protein Kinase–Dependent Manner to Promote Myofibroblast Differentiation and Tissue Fibrosis in Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Members of the superfamily of nuclear receptors have been implicated in inflammatory processes and pathologic tissue remodeling and have emerged as attractive targets for pharmaceutical intervention. However, the role of testicular receptor 4 (TR4; or Nr2c2) in fibroblast activation and rheumatologic diseases has not yet been investigated ...
Yun Zhang   +16 more
wiley   +1 more source

ADAM Report #20 (March1999)

open access: yes, 1999
ADAM REPORT # 20, March 1999 1. Wage Trends • Wage Increases in December '98 Quarter Agreements • Wage Trends in Current Agreements • Wage Dispersions • High Wage Agreements • Federal AWAs • Wage Trends in AWAs 2.
ACIRRT; Australian Centre for Industrial Relations Research and Training
core  

Complement activation linked to type II interferon signaling in Still disease

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Still disease (SD) is an autoinflammatory syndrome characterized by innate immune dysregulation. While complement can drive inflammation, its involvement in SD remains to be defined. Thus, we aimed to assess complement activation in SD. Methods Complement was assessed using transcriptomic, proteomic, and in vitro approaches. RNA sequencing of
Freya M.C.H. Huijsmans   +115 more
wiley   +1 more source

Adam J. Gabris

open access: yes, 1999
Adam J. Gabris, 2007 Baseball Inductee to the Billiken Hall of Fame (Graduate of the College of Public Service ...
Unknown creator; St. Louis University
core  

CD248/Endosialin regulates synovial fibroblast state to control coupling of inflammation and bone damage in murine models of immune‐mediated inflammatory arthritis and ageing

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Synovial fibroblasts directly contribute to inflammation and damage in immune‐mediated inflammatory arthritis. CD248/Endosialin is expressed by fibroblasts in the synovium, is highly upregulated during inflammation and has been proposed as a potential therapeutic target.
Samuel Kemble   +12 more
wiley   +1 more source

ADAM Report 3

open access: yes, 1994
ADAM REPORT # 3, July 1994 1. Overview and Industry Trends 2. Innovations in Agreements 3.
ACIRRT
core  

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy